AbbVie price target raised to $195 from $185 at UBS

UBS raised the firm’s price target on AbbVie to $195 from $185 and keeps a Neutral rating on the shares ahead of the Q3 results. The firm is broadly in-line with consensus on Q3 sales, and forecasts U.S. Humira erosion of 37% for $1.9B in the quarter, slightly lower than consensus, the analyst tells investors in a research note. Aesthetics remains “tough” and UBS expects more of an inflection in Q4, the firm adds.